Crispr Therapeutics AG (CRSP) Stock Price Today
Michael Burry bets against AI hype, buying call options on beaten-down stocks like UnitedHealth, Regeneron, and Lululemon.
Michael Burry, known for his contrarian investing style, is avoiding popular AI stocks and instead buying call options on three undervalued companies: UnitedHealth, Regeneron, and Lululemon. He believes these stocks were unfairly punished and are poi...
Computacenter shares drop 6% despite raised profit guidance and higher price targets from Jefferies.
Computacenter PLC shares fell 6% even after the company raised its adjusted pretax profit guidance to at least £380 million for 2026, surpassing consensus estimates. Jefferies increased its earnings per share forecasts for 2026 and 2027, raising its ...
Helium One seen as top pick in helium sector amid rising demand and supply constraints
Panmure Liberum identifies Helium One Global Ltd as a leading investment opportunity in the helium market, which faces rising demand expected to double by 2035 and structural supply shortages. The company’s projects in Tanzania and the US offer expos...
Graphene Manufacturing Group expands sales team in Asia Pacific to boost growth in key markets.
Graphene Manufacturing Group Ltd has launched a dedicated sales team for the Asia Pacific region, targeting India, South Korea, Japan, and Singapore, in addition to its existing operations in Australia. This expansion supports the company's global co...
BioVie advances Parkinson’s Phase 3 trial plans after positive Phase 2 results and FDA engagement.
BioVie Inc is preparing to advance its Phase 3 clinical trial for bezisterim, a drug targeting Parkinson’s disease, following promising Phase 2 results. The company has requested an End-of-Phase 2 meeting with the FDA to finalize the Phase 3 trial de...
Amgen downgraded after Novartis trial failure raises doubts on cholesterol drug prospects
Investment firm BMO Capital downgraded Amgen's stock from "Outperform" to "Market Perform" following a major clinical trial failure by Novartis for a similar cholesterol drug. Novartis' drug pelacarsen failed in a late-stage Phase III trial, casting ...
New report reveals growing demand for connected, supportive maternal and baby care solutions in the U.S.
NIQ and Momcozy's 2026 U.S. Mother & Baby Market Trends Report highlights how high-frequency caregiving, information overload, and evolving trust signals are reshaping the maternal and baby care market. The study of 1,240 U.S. mothers shows that moth...
Gold X2 Mining begins trading on NYSE American, expanding U.S. investor access.
Gold X2 Mining Inc. has started trading its common shares on the NYSE American under the ticker AUXX, while continuing on the TSX Venture Exchange. This move aims to broaden the company's investor base and increase visibility in U.S. capital markets....
Al Shams plans to nominate new directors at Braemar amid concerns over governance and a tight nomination window.
Al Shams Investments, the largest shareholder of Braemar Hotels & Resorts, announced its intention to nominate a full slate of independent directors to the company's board. This move follows Braemar's announcement of a compressed nomination window co...
Novartis shares drop after late-stage drug trial failures, but long-term growth outlook remains intact
Novartis shares fell sharply following the failure of its late-stage drug candidates pelacarsen and del-desiran in phase 3 trials, which impacts the company’s near-term growth prospects. Despite these setbacks, Novartis reaffirmed its revenue growth ...
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.